Dr. Reddy's Laboratories share price
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,239.00.
- Next results date: the board meets on 23 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,02,624 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Jul 2026
- 31.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.65%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Jul 2026
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Jul 2026
- 6.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.16
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 15,50,20651.1% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Sep 2026, against the quarter beforeFiled 23 Oct
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8,698 Crup 7.38%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹913 Crup 109.64%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 10.5%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Dec 2024Filed 24 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 23 Jul | Sep 2025Filed 24 Oct | Dec 2025Filed 21 Jan | Mar 2026Filed 12 May | Jun 2026Filed 22 Jul | Sep 2026Filed 23 Oct |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 |
| Net profit | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 16.8% | 18.6% | 16.4% | 15.1% | 13.6% | 2.9% | 5.4% | 10.5% |
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Global GenericsGlobal Generics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹29,946 Crup 3.33%87.0%
- Pharmaceutical Services and Active IngredientsPharmaceutical Services and Active Ingredients, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹4,267 Crdown 2.73%12.4%
- OthersOthers, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹214 Cr0.6%
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 64% of 2,480 trading days over the last 10 years.
At or below today's level on 3% of 1,980 trading days since Oct 2018.
At or below today's level on 76% of 1,980 trading days since Oct 2018.
At or below today's level on 45% of 2,476 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +10.3% | −25.7% | +47.7% | 0.6% |
| 3 years | +11.4% | −2.4% | +13.5% | 0.7% |
| 5 years | +7.5% | +16.5% | −8.3% | 0.7% |
Mutual funds holding it
282 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 143 of the 187 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 18
- AddedAdded. Funds that held more shares than at the end of the month before.
- 127
- CutCut. Funds that held fewer shares than at the end of the month before.
- 60
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 68
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,44,58,054 | 1.23% | ₹1,782.7 Cr |
 SBI Nifty 50 ETFSBI Mutual Fund | 1,18,28,947 | 0.72% | ₹1,458.5 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 95,69,430 | 2.06% | ₹1,179.9 Cr |
| ICICI Prudential India Opportunities FundICICI Prudential Mutual Fund | 78,44,672 | 2.65% | ₹967.2 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 63,19,449 | 1.02% | ₹779.2 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 54,14,201 | 9.73% | ₹667.6 Cr |
 UTI Nifty 50 ETFUTI Mutual Fund | 40,56,687 | 0.72% | ₹500.2 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 40,49,746 | 5.45% | ₹499.3 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 40,01,922 | 0.96% | ₹493.4 Cr |
| Nippon India ETF Nifty 50 BeESNippon India Mutual Fund | 37,97,469 | 0.72% | ₹468.2 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Dr. Reddy's Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 10 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹8.00 |
| 10 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹8.00 |
| 16 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹40.00 |
| 11 Jul 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹40.00 |
| 11 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹30.00 |
| 9 Jul 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹25.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Dr. Reddy's Laboratories share price by year
Each calendar year to 2025.Dr. Reddy's Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,271.40 | −8.4% | 1,375.05 | 1,087.90 |
| 2024 | 1,388.50 | +19.7% | 1,412.49 | 1,127.08 |
| 2023 | 1,159.58 | +36.8% | 1,190.67 | 840.19 |
| 2022 | 847.51 | −13.6% | 970.63 | 743.77 |
| 2021 | 981.40 | −5.7% | 1,115.14 | 842.55 |
| 2020 | 1,041.02 | +81.1% | 1,066.67 | 524.79 |
| 2019 | 574.91 | +9.9% | 595.35 | 498.51 |
| 2018 | 523.30 | +8.4% | 544.44 | 378.61 |
| 2017 | 482.84 | −21.1% | 631.83 | 386.22 |
| 2016 | 612.08 | −1.6% | 735.33 | 551.42 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,236.20 | 1,250.60 | 1,215.60 | 1,229.50 | 1,229.84 | 15,50,206 | 51.1% |
| 22 Oct 2026 | 1,236.00 | 1,250.70 | 1,212.70 | 1,239.00 | 1,232.20 | 28,05,310 | 53.1% |
| 21 Oct 2026 | 1,245.00 | 1,252.00 | 1,232.50 | 1,244.50 | 1,241.85 | 12,23,759 | 52.2% |
| 19 Oct 2026 | 1,232.00 | 1,245.00 | 1,227.00 | 1,242.50 | 1,237.37 | 10,23,837 | 47.8% |
| 16 Oct 2026 | 1,222.00 | 1,233.00 | 1,214.10 | 1,233.00 | 1,223.95 | 12,61,028 | 52.7% |
| 15 Oct 2026 | 1,211.10 | 1,234.20 | 1,206.60 | 1,218.80 | 1,224.48 | 13,92,873 | 53.0% |
| 14 Oct 2026 | 1,234.20 | 1,234.40 | 1,209.60 | 1,216.00 | 1,218.27 | 16,15,685 | 55.4% |
| 13 Oct 2026 | 1,230.90 | 1,250.70 | 1,223.30 | 1,240.00 | 1,242.51 | 24,17,763 | 50.8% |
| 12 Oct 2026 | 1,197.00 | 1,235.00 | 1,196.90 | 1,229.40 | 1,225.97 | 17,56,682 | 45.8% |
| 9 Oct 2026 | 1,180.00 | 1,200.80 | 1,172.00 | 1,197.00 | 1,193.94 | 15,10,336 | 65.4% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 28 Oct 2024 | Split | 0.2000 | Each share became 5. |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited is a pharmaceutical company headquartered in Hyderabad, India. Its portfolio includes active pharmaceutical ingredients (APIs), generic formulations including biosimilars, over-the-counter (OTC) products, novel products and custom pharmaceutical services. Its key therapeutic areas include oncology, central nervous system, pain management, gastro-intestinal and cardiovascular. Its major markets include the USA, India, Russia and the Commonwealth of Independent States (CIS), China, Brazil and Europe.
It operates through three business segments. Global Generics develops, manufactures and sells branded and unbranded prescription medicines in developed and emerging markets, and includes the biosimilars and consumer health businesses. Pharmaceutical Services and Active Ingredients covers APIs and intermediates, semi-finished and finished formulations, and discovery and contract development and manufacturing through Aurigene Pharmaceutical Services Limited, a wholly owned subsidiary. The third segment, Others, includes Aurigene Oncology Limited, a wholly owned subsidiary that advances oncology assets, and a proprietary products business.
The company has 24 manufacturing facilities. Its nine API units are in India, Mexico, the United Kingdom and the United States, and it operates a manufacturing facility in China through a joint venture. It serves patients in 88 countries and has 27,527 employees.
Dr. Kallam Anji Reddy founded the company. It was incorporated in 1984. In 2024 it acquired a portfolio of nicotine replacement therapy (NRT) brands outside the United States from Haleon plc. The brands, anchored by Nicotinell, are present in over 30 countries. The company's shares are also listed on the New York Stock Exchange. The board has two promoter directors. A promoter is the person or group that set up a company or controls it.
- Legal name
- Dr. Reddy's Laboratories Limited
- NSE symbol
- DRREDDY
- BSE code
- 500124
- ISIN
- INE089A01031
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 1986 on BSE, May 2003 on NSE
- Face value
- ₹1
- CIN
- L85195TG1984PLC004507
- Corporate identity number, the registrar of companies' code for it